Esculetin (6, 7-dihydroxycoumarin): A potential cancer chemopreventive agent through suppression of Sp1 in oral squamous cancer cells

International Journal of Oncology

Volumn 46, Issue 1, 2015, Pages 265-271

  Cho, Jin Hyoung ^a   Shin, Jae Cheon ^b   Cho, Jung Jae ^c   Choi, Yung Hyun ^c   Shim, Jung Hyun ^b   Chae, Jung Il ^a  

^a Chonbuk National University   (South Korea)

^b Mokpo National University   (South Korea)

^c Dong Eui University   (South Korea)

Author keywords

Apoptosis; Esculetin; Oral squamous cell carcinoma; Specificity protein 1

Indexed keywords

ANTINEOPLASTIC AGENT; ESCULETIN; TRANSCRIPTION FACTOR SP1; UMBELLIFERONE DERIVATIVE;

APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL SURVIVAL; CHEMOPROPHYLAXIS; DOWN REGULATION; DRUG EFFECTS; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MOUTH NEOPLASMS; PATHOLOGY; PROCEDURES; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL SURVIVAL; CHEMOPREVENTION; DOWN-REGULATION; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOUTH NEOPLASMS; SP1 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED; UMBELLIFERONES;

EID: 84917708516     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2700     Document Type: Article

References (30)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Hamada T, Wakamatsu T, Miyahara M, et al: MUC4: a novel prognostic factor of oral squamous cell carcinoma. Int J Cancer 130: 1768-1776, 2012.
3. Kruger M, Hansen T, Kasaj A and Moergel M: The correlation between chronic periodontitis and oral cancer. Case Rep Dent 2013: 262410, 2013.
4. Forastiere A, Koch W, Trotti A and Sidransky D: Head and neck cancer. N Engl J Med 345: 1890-1900, 2001.
5. Liang XH, Lewis J, Foote R, Smith D and Kademani D: Prevalence and significance of human papillomavirus in oral tongue cancer: the Mayo Clinic experience. J Oral Maxillofac Surg 66: 1875-1880, 2008.
6. Warnakulasuriya S: Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 45: 309-316, 2009.
7. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
8. Chang WS, Lin CC, Chuang SC and Chiang HC: Superoxide anion scavenging effect of coumarins. Am J Chin Med 24: 11-17, 1996.
9. Masamoto Y, Ando H, Murata Y, Shimoishi Y, Tada M and Takahata K: Mushroom tyrosinase inhibitory activity of esculetin isolated from seeds of Euphorbia lathyris L. Biosci Biotechnol Biochem 67: 631-634, 2003.
10. Lin WL, Wang CJ, Tsai YY, Liu CL, Hwang JM and Tseng TH: Inhibitory effect of esculetin on oxidative damage induced by t-butyl hydroperoxide in rat liver. Arch Toxicol 74: 467-472, 2000.
11. Egan D, O'Kennedy R, Moran E, Cox D, Prosser E and Thornes RD: The pharmacology, metabolism, analysis, and applications of coumarin and coumarin-related compounds. Drug Metab Rev 22: 503-529, 1990.
12. Okada Y, Miyauchi N, Suzuki K, et al: Search for naturally occurring substances to prevent the complications of diabetes. II. Inhibitory effect of coumarin and flavonoid derivatives on bovine lens aldose reductase and rabbit platelet aggregation. Chem Pharm Bull (Tokyo) 43: 1385-1387, 1995.
13. Wang CJ, Hsieh YJ, Chu CY, Lin YL and Tseng TH: Inhibition of cell cycle progression in human leukemia HL-60 cells by esculetin. Cancer Lett 183: 163-168, 2002.
14. Kok SH, Yeh CC, Chen ML and Kuo MY: Esculetin enhances TRAIL-induced apoptosis through DR5 upregulation in human oral cancer SAS cells. Oral Oncol 45: 1067-1072, 2009.
15. Noguchi M, Kitagawa H, Miyazaki I and Mizukami Y: Influence of esculetin on incidence, proliferation, and cell kinetics of mammary carcinomas induced by 7, 12-dimethylbenz[a]anthracene in rats on high- and low-fat diets. Jpn J Cancer Res 84: 1010-1014, 1993.
16. Davie JR, He S, Li L, et al: Nuclear organization and chromatin dynamics-Sp1, Sp3 and histone deacetylases. Adv Enzyme Regul 48: 189-208, 2008.
17. Chuang JY, Wu CH, Lai MD, Chang WC and Hung JJ: Overexpression of Sp1 leads to p53-dependent apoptosis in cancer cells. Int J Cancer 125: 2066-2076, 2009.
18. Chen L, Liu Q, Qin R, et al: Amplification and functional characterization of MUC1 promoter and gene-virotherapy via a targeting adenoviral vector expressing hSSTR2 gene in MUC1- positive Panc-1 pancreatic cancer cells in vitro. Int J Mol Med 15: 617-626, 2005.
19. Kong LM, Liao CG, Fei F, Guo X, Xing JL and Chen ZN: Transcription factor Sp1 regulates expression of cancer-associated molecule CD147 in human lung cancer. Cancer Sci 101: 1463-1470, 2010.
20. Sankpal UT, Goodison S, Abdelrahim M and Basha R: Targeting Sp1 transcription factors in prostate cancer therapy. Med Chem 7: 518-525, 2011.
21. Chae JI, Jeon YJ and Shim JH: Downregulation of Sp1 is involved in honokiol-induced cell cycle arrest and apoptosis in human malignant pleural mesothelioma cells. Oncol Rep 29: 2318-2324, 2013.
22. Kim DW, Ko SM, Jeon YJ, et al: Anti-proliferative effect of honokiol in oral squamous cancer through the regulation of specificity protein 1. Int J Oncol 43: 1103-1110, 2013.
23. Chae JI, Cho JH, Lee KA, et al: Role of transcription factor Sp1 in the quercetin-mediated inhibitory effect on human malignant pleural mesothelioma. Int J Mol Med 30: 835-841, 2012.
24. Jeon YJ, Ko SM, Cho JH, Chae JI and Shim JH: The HDAC inhibitor, panobinostat, induces apoptosis by suppressing the expresssion of specificity protein 1 in oral squamous cell carcinoma. Int J Mol Med 32: 860-866, 2013.
25. Kawase M, Sakagami H, Hashimoto K, Tani S, Hauer H and Chatterjee SS: Structure-cytotoxic activity relationships of simple hydroxylated coumarins. Anticancer Res 23: 3243-3246, 2003.
26. Tubaro A, Del Negro P, Ragazzi E, Zampiron S and Della Loggia R: Anti-inflammatory and peripheral analgesic activity of esculetin in vivo. Pharmacol Res Commun 20 (Suppl 5): 83-85, 1988.
27. Huang HC, Lai MW, Wang HR, Chung YL, Hsieh LM and Chen CC: Antiproliferative effect of esculetin on vascular smooth muscle cells: possible roles of signal transduction pathways. Eur J Pharmacol 237: 39-44, 1993.
28. Matsunaga K, Yoshimi N, Yamada Y, et al: Inhibitory effects of nabumetone, a cyclooxygenase-2 inhibitor, and esculetin, a lipoxygenase inhibitor, on N-methyl-N-nitrosourea-induced mammary carcinogenesis in rats. Jpn J Cancer Res 89: 496-501, 1998.
29. Hecht SS, Kenney PM, Wang M, et al: Evaluation of butylated hydroxyanisole, myo-inositol, curcumin, esculetin, resveratrol and lycopene as inhibitors of benzo[a]pyrene plus 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in A/J mice. Cancer Lett 137: 123-130, 1999.
30. Martin-Aragon S, Benedi JM and Villar AM: Effects of the antioxidant (6, 7-dihydroxycoumarin) esculetin on the glutathione system and lipid peroxidation in mice. Gerontology 44: 21-25, 1998.